Subtopic Deep Dive
Antimicrobial Treatment of Rhodococcus equi
Research Guide
What is Antimicrobial Treatment of Rhodococcus equi?
Antimicrobial treatment of Rhodococcus equi involves macrolide-rifampin combinations for pneumonia in foals and humans, with protocols addressing resistance in macrolides and rifampin.
Rhodococcus equi causes suppurative pneumonia primarily in foals and immunocompromised humans. Studies compare azithromycin-rifampin, clarithromycin-rifampin, and erythromycin-rifampin efficacy (Giguère et al., 2004, 134 citations). Resistance prevalence reached 62% posttreatment on farms using mass therapy (Burton et al., 2013, 102 citations). Over 10 papers since 1994 document 173 human cases and foal outcomes.
Why It Matters
Optimizing macrolide-rifampin therapy reduces foal mortality on endemic farms, where resistance rose from 24% pretreatment to 62% posttreatment (Burton et al., 2013). In humans, prolonged combinations treat disseminated infections, as reviewed in 12 Oklahoma cases and global literature (Verville et al., 1994). Giguère et al. (2010) reported 35% resistance prevalence, with 71% survival in resistant foal cases using alternative antimicrobials like gentamicin. Protocols prevent treatment failures amid genomic virulence factors (Letek et al., 2010).
Key Research Challenges
Macrolide-Rifampin Resistance
Mass treatment of subclinical foals increased resistance from 24% to 62% on a Kentucky farm (Burton et al., 2013). Giguère et al. (2010) found 35% of isolates resistant, with 71% foal survival using alternatives. Prevalence tracking guides protocol shifts.
Subclinical Lesion Management
Antimicrobial therapy failed to accelerate healing of subclinical pulmonary abscesses (Venner et al., 2011, 99 citations). Mass treatment showed no benefit over monitoring (Venner et al., 2012, 91 citations). Balancing overtreatment risks resistance.
Human Case Variability
R. equi causes diverse infections in immunocompromised patients, with 173 citations reviewing 12 cases (Verville et al., 1994). Optimal duration and combinations remain unstandardized versus foal protocols (Linder, 1997).
Essential Papers
Rhodococcus equi Infections of Humans
THOMAS D. VERVILLE, Mark M. Huycke, Ronald A. Greenfield et al. · 1994 · Medicine · 173 citations
Increased recognition of Rhodococcus equi as a human pathogen has occurred since 1983, when the first review article summarized the world's literature of 12 cases. In this article, we present 12 ca...
The Genome of a Pathogenic Rhodococcus: Cooptive Virulence Underpinned by Key Gene Acquisitions
Michal Letek, Patricia González, Iain MacArthur et al. · 2010 · PLoS Genetics · 154 citations
We report the genome of the facultative intracellular parasite Rhodococcus equi, the only animal pathogen within the biotechnologically important actinobacterial genus Rhodococcus. The 5.0-Mb R. eq...
Retrospective Comparison of Azithromycin, Clarithromycin, and Erythromycin for the Treatment of Foals with <i>Rhodococcus equi</i> Pneumonia
Steeve Giguère, Stephanie Jacks, Gregory Roberts et al. · 2004 · Journal of Veterinary Internal Medicine · 134 citations
The objective of this retrospective study was to compare the efficacy of azithromycin‐rifampin, clarithromycin‐rifampin, and erythromycin‐rifampin for the treatment of pneumonia caused by Rhodococc...
Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of R equi
Steeve Giguère, Elise Lee, Elliott Williams et al. · 2010 · Journal of the American Veterinary Medical Association · 125 citations
Abstract Objective —To determine the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and to describe treatment outcome in foals infected ...
Macrolide- and Rifampin-Resistant<i>Rhodococcus equi</i>on a Horse Breeding Farm, Kentucky, USA
Alexandra J. Burton, Steeve Giguère, Tracy L. Sturgill et al. · 2013 · Emerging infectious diseases · 102 citations
Macrolide and rifampin resistance developed on a horse breeding farm after widespread use was instituted for treatment of subclinical pulmonary lesions in foals. Resistance occurred in 6 (24%) of 2...
Failure of antimicrobial therapy to accelerate spontaneous healing of subclinical pulmonary abscesses on a farm with endemic infections caused by Rhodococcus equi
Monica Venner, Anne Rödiger, Marc Laemmer et al. · 2011 · The Veterinary Journal · 99 citations
<i>Rhodococcus equi</i> and <i>Arcanobacterium haemolyticum</i>: Two "Coryneform" Bacteria Increasingly Recognized as Agents of Human Infection
Regina Linder · 1997 · Emerging infectious diseases · 93 citations
Rhodococcus equi and Arcanobacterium haemolyticum, formerly classified in the genus Corynebacterium, are members of the loosely defined taxon "coryneform" bacteria. Although they are the etiologic ...
Reading Guide
Foundational Papers
Read Verville et al. (1994) first for 173-cited human case synthesis, then Giguère et al. (2004) for 134-cited macrolide benchmarks in foals, and Letek et al. (2010) for genomic basis.
Recent Advances
Study Burton et al. (2013, 102 citations) on resistance emergence, Venner et al. (2011, 99 citations) on subclinical failures, and Venner et al. (2012, 91 citations) on mass treatment inefficacy.
Core Methods
Retrospective cohort comparisons of survival and lesions (Giguère et al., 2004); MIC prevalence surveys (Giguère et al., 2010); ultrasonographic monitoring of abscesses (Venner et al., 2011).
How PapersFlow Helps You Research Antimicrobial Treatment of Rhodococcus equi
Discover & Search
PapersFlow's Research Agent uses searchPapers and exaSearch to find Giguère et al. (2004) on macrolide comparisons, then citationGraph reveals 134 citing works on resistance, and findSimilarPapers uncovers Venner et al. (2011) for subclinical treatment failures.
Analyze & Verify
Analysis Agent applies readPaperContent to extract resistance rates from Burton et al. (2013), verifies survival stats with verifyResponse (CoVe), and runs PythonAnalysis on prevalence data from Giguère et al. (2010) for statistical trends using pandas, with GRADE grading for evidence strength in foal outcomes.
Synthesize & Write
Synthesis Agent detects gaps in human versus equine protocols from Verville et al. (1994) and Giguère et al. (2004), flags contradictions in mass therapy efficacy (Venner et al., 2012), while Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to produce reports with exportMermaid for resistance timelines.
Use Cases
"Compare azithromycin vs clarithromycin efficacy in R. equi foal pneumonia"
Research Agent → searchPapers('Giguère 2004') → Analysis Agent → readPaperContent + runPythonAnalysis (survival curves) → outputs efficacy table with p-values.
"Draft LaTeX review on R. equi resistance protocols"
Synthesis Agent → gap detection (Burton 2013, Giguère 2010) → Writing Agent → latexEditText + latexSyncCitations + latexCompile → outputs compiled PDF with cited figures.
"Find code for R. equi MIC analysis from papers"
Research Agent → paperExtractUrls (Letek 2010 genome) → Code Discovery → paperFindGithubRepo + githubRepoInspect → outputs Python scripts for genomic resistance prediction.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'Rhodococcus equi resistance', structures reports comparing Giguère et al. (2004, 2010) outcomes with GRADE scores. DeepScan applies 7-step CoVe to verify resistance prevalence from Burton et al. (2013), checkpointing stats. Theorizer generates hypotheses on genomic drivers (Letek et al., 2010) for new combinations.
Frequently Asked Questions
What defines antimicrobial treatment of Rhodococcus equi?
Macrolide-rifampin combinations treat R. equi pneumonia in foals and humans, with azithromycin-rifampin showing superior efficacy to erythromycin-rifampin (Giguère et al., 2004).
What methods evaluate treatment efficacy?
Retrospective studies compare survival rates and ultrasonographic lesion resolution in foals (Giguère et al., 2004; Venner et al., 2012). MIC testing assesses resistance (Giguère et al., 2010).
What are key papers?
Verville et al. (1994, 173 citations) reviews human cases; Giguère et al. (2004, 134 citations) compares macrolides; Burton et al. (2013, 102 citations) documents farm resistance.
What open problems exist?
Standardizing human protocols versus foal data; alternatives to macrolides post-resistance; preventing subclinical overtreatment (Venner et al., 2011).
Research Infectious Disease Case Reports and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Antimicrobial Treatment of Rhodococcus equi with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers